186 related articles for article (PubMed ID: 9029406)
21. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.
Kanthasamy A; Sprague JE; Shotwell JR; Nichols DE
Neuroscience; 2002; 114(4):917-24. PubMed ID: 12379247
[TBL] [Abstract][Full Text] [Related]
22. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.
Gudelsky GA; Nash JF
J Neurochem; 1996 Jan; 66(1):243-9. PubMed ID: 8522960
[TBL] [Abstract][Full Text] [Related]
23. Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression.
Jaehne EJ; Majumder I; Salem A; Irvine RJ
Addict Biol; 2011 Jan; 16(1):7-19. PubMed ID: 20192951
[TBL] [Abstract][Full Text] [Related]
24. Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats.
Piper BJ; Ali SF; Daniels LG; Meyer JS
Synapse; 2010 Jun; 64(6):421-31. PubMed ID: 20169574
[TBL] [Abstract][Full Text] [Related]
25. Studies on the mechanism of p-chloroamphetamine neurotoxicity.
Sprague JE; Johnson MP; Schmidt CJ; Nichols DE
Biochem Pharmacol; 1996 Oct; 52(8):1271-7. PubMed ID: 8937435
[TBL] [Abstract][Full Text] [Related]
26. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin.
Shankaran M; Gudelsky GA
Pharmacol Biochem Behav; 1998 Dec; 61(4):361-6. PubMed ID: 9802829
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists.
Gudelsky GA; Yamamoto BK; Nash JF
Eur J Pharmacol; 1994 Nov; 264(3):325-30. PubMed ID: 7698172
[TBL] [Abstract][Full Text] [Related]
28. MDMA induced dopamine release in vivo: role of endogenous serotonin.
Koch S; Galloway MP
J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077
[TBL] [Abstract][Full Text] [Related]
29. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Sanchez V; Camarero J; Esteban B; Peter MJ; Green AR; Colado MI
Br J Pharmacol; 2001 Sep; 134(1):46-57. PubMed ID: 11522596
[TBL] [Abstract][Full Text] [Related]
30. MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition.
Gyongyosi N; Balogh B; Kirilly E; Kitka T; Kantor S; Bagdy G
Brain Res; 2008 Sep; 1231():34-46. PubMed ID: 18638459
[TBL] [Abstract][Full Text] [Related]
31. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
Wang X; Baumann MH; Xu H; Rothman RB
Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
[TBL] [Abstract][Full Text] [Related]
32. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum.
Shankaran M; Yamamoto BK; Gudelsky GA
J Neurochem; 1999 Jun; 72(6):2516-22. PubMed ID: 10349862
[TBL] [Abstract][Full Text] [Related]
33. Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET.
Li IH; Huang WS; Shiue CY; Huang YY; Liu RS; Chyueh SC; Hu SH; Liao MH; Shen LH; Liu JC; Ma KH
Neuroimage; 2010 Jan; 49(2):1259-70. PubMed ID: 19682588
[TBL] [Abstract][Full Text] [Related]
34. Long-lasting neuroprotective effect of sildenafil against 3,4-methylenedioxymethamphetamine- induced 5-hydroxytryptamine deficits in the rat brain.
Puerta E; Barros-Miñones L; Hervias I; Gomez-Rodriguez V; Orejana L; Pizarro N; de la Torre R; Jordán J; Aguirre N
J Neurosci Res; 2012 Feb; 90(2):518-28. PubMed ID: 21948520
[TBL] [Abstract][Full Text] [Related]
35. On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.
Goñi-Allo B; Puerta E; Mathúna BO; Hervias I; Lasheras B; de la Torre R; Aguirre N
Neuropharmacology; 2008 Apr; 54(5):885-900. PubMed ID: 18329670
[TBL] [Abstract][Full Text] [Related]
36. Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats.
Wallinga AE; Grahlmann C; Granneman RA; Koolhaas JM; Buwalda B
Brain Res; 2011 Jun; 1398():13-20. PubMed ID: 21620380
[TBL] [Abstract][Full Text] [Related]
37. Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain.
Bhide NS; Lipton JW; Cunningham JI; Yamamoto BK; Gudelsky GA
Brain Res; 2009 Aug; 1286():32-41. PubMed ID: 19555677
[TBL] [Abstract][Full Text] [Related]
38. In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism.
Colado MI; O'Shea E; Esteban B; Granados R; Green AR
Neuropharmacology; 1999 Feb; 38(2):307-14. PubMed ID: 10218873
[TBL] [Abstract][Full Text] [Related]
39. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity.
Fone KC; Beckett SR; Topham IA; Swettenham J; Ball M; Maddocks L
Psychopharmacology (Berl); 2002 Feb; 159(4):437-44. PubMed ID: 11823897
[TBL] [Abstract][Full Text] [Related]
40. Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine.
Hatzidimitriou G; Tsai EH; McCann UD; Ricaurte GA
Synapse; 2002 Apr; 44(1):51-7. PubMed ID: 11842446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
